Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study
Wallington, Michael, Guillaume, Xavier, Mulvihill, Emily, Wayser, Graceanne R, Kaul, Vandana, Graziani-Taugeron, Claire, Shahkarami, Mina, Ryan, Kellie J.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
CLL-471 Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab (VenO) Versus Covalent Bruton's Tyrosine Kinase Inhibitors (BTKis) ± Anti-CD20 Therapy Among Patients With Chronic Lymphocytic Leukemia (CLL) in the United States (US)
Li, Sophia S., Ravelo, Arliene, Schuldt, Robert, Shahkarami, Mina, Thompson, Meghan C.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab (VenO) Versus Covalent Bruton's Tyrosine Kinase Inhibitors (BTKis) ± Anti-CD20 Therapy Among Patients With Chronic Lymphocytic Leukemia (CLL) in the United States (US)
Li, Sophia S., Ravelo, Arliene, Schuldt, Robert, Shahkarami, Mina, Thompson, Meghan C.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
Davids, Matthew S., Sharman, Jeff P., Eyre, Toby A., Woyach, Jennifer A., de Miranda, Paulo Andre P., Shahkarami, Mina, Butturini, Anna, Emeribe, Ugochinyere, Byrd, John C.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Davids, Matthew S., Mato, Anthony R., Hum, Juliette, Wargo, Susana, Emeribe, Ugochinyere, Shahkarami, Mina, Sokolowski, Kevin, Biondo, Juliana M.L., Abhyankar, Sarang, Hermann, Rick, Sharman, Jeff P.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Ryan, Christine E, Davids, Matthew S, Hermann, Richard, Shahkarami, Mina, Biondo, Juliana, Abhyankar, Sarang, Alhasani, Hasan, Sharman, Jeff P, Mato, Anthony R, Roeker, Lindsey E
Published in Future oncology (London, England) (01.10.2022)
Published in Future oncology (London, England) (01.10.2022)
Get full text
Journal Article
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Davids, Matthew S., Sharman, Jeff P., Ghia, Paolo, Woyach, Jennifer A., Eyre, Toby A., Jurczak, Wojciech, Siddiqi, Tanya, Miranda, Paulo, Shahkarami, Mina, Butturini, Anna, Emeribe, Ugochinyere, Byrd, John C.
Published in Blood advances (09.07.2024)
Published in Blood advances (09.07.2024)
Get full text
Journal Article
Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer
Beney, Johnny, Devine, E Beth, Chow, Valby, Ignoffo, Robert J, Mitsunaga, Lisa, Shahkarami, Mina, McMillan, Alex, Bero, Lisa A
Published in Pharmacotherapy (01.10.2002)
Published in Pharmacotherapy (01.10.2002)
Get more information
Journal Article